Anne Peters, MD
Articles
September 20th 2016
Representativeness of Dipeptidyl-Peptidase-4 Inhibitor Cardiovascular Outcomes Trials
Joanna P. MacEwan, PhD John J Sheehan, PhD Anne Peters, MD Jacqueline Vanderpuye-Orgle, PhD Iftekhar Kalsekar, PhD Anup Malani, PhD
Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.
July 2nd 2013
Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
Michael E. Chernew, PhD Rick McKellar, BS Wade Aubry, MD Roy Beck, MD, PhD Joshua Benner, PharmD, ScD Jan E. Berger, MD, MJ A. Mark Fendrick, MD Felicia Forma, BSc Dana Goldman, PhD Anne Peters, MD Rebecca Killion, MA Darius Lakdawalla, PhD Douglas K. Owens, MD Joe Stahl, MA
February 12th 2013
Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
Michael E. Chernew, PhD Rick McKellar, BS Wade Aubry, MD Roy Beck, MD, PhD Joshua Benner, PharmD, ScD Jan E. Berger, MD, MJ A. Mark Fendrick, MD Felicia Forma, BSc Dana Goldman, PhD Anne Peters, MD Rebecca Killion, MA Darius Lakdawalla, PhD Douglas K. Owens, MD Joe Stahl, MA
Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 21st 2024 | Updated: November 23rd 2024
Polygenic Risk Scores Can Identify Patients Who Should Receive IOP-Lowering Treatment
